OGT will be moving from plastic packaging to new, sustainable packaging for CytoCell products, an important step forward in our ongoing environmental efforts.
Read articleOGT will be moving from plastic packaging to new, sustainable packaging for CytoCell products, an important step forward in our ongoing environmental efforts.
ReadUltra-low variant detection (including very large FLT3-ITDs) enables a stronger characterization of a sample’s current AML status.
ReadImproving upon existing SureSeq™ technology, this latest SureSeq NGS panel unlocks more efficient and expansive genetic profiling for CLL samples
ReadEnables users to replace multiple techniques with a single streamlined NGS process for faster results.
ReadInvestment in new premises to create increase in cutting-edge genomic solutions and collaborative partnerships.
ReadNew NGS assay delivers exceptional coverage, providing a rapid and highly sensitive means of investigating MRD in AML samples
ReadEnhanced NGS portfolio includes Interpret Software updates and enables rapid and confident variant detection even in difficult-to-sequence regions.
ReadExpansion of access to clinical support network and market-leading genomic solutions aims to improve patient outcomes.
ReadNew leadership will drive OGT’s mission to improve clinical care by partnering with customers.
ReadCytoCell® University offers extensive FISH expertise and reaffirms commitment to customer support and training.
ReadNew integrated website, expanded resources and substantial worldwide support reaffirm partnership and commitment to customers.
ReadIn the workshop users will explain how OGT’s SureSeq™ NGS panels can increase throughput and save time and cost in the detection of a wide variety of aberrations.
Read